Literature DB >> 10745240

Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine.

M Muszkat1, A B Yehuda, M H Schein, Y Friedlander, P Naveh, E Greenbaum, M Schlesinger, R Levy, Z Zakay-Rones, G Friedman.   

Abstract

Intramuscular (IM) influenza vaccines are about 50% effective in preventing clinical illness among the elderly and their effectiveness in eliciting mucosal response may be even lower. The aim of the present study was to evaluate the immunological effect of a novel inactivated intranasal (IN) trivalent whole influenza virus vaccine among community-dwelling elderly. Sixty-one subjects were vaccinated with two doses of an IN vaccine and a control group of 31 subjects was vaccinated with a commercial IM vaccine. Viral strains in the 1997/8 vaccine used were A/Nanchang/933/95(H3N2), A/Johannesburg/82/96(H1N1) and B/Harbin/7/94. Serum IgG and nasal IgA were determined by HI and ELISA, respectively. Only a few minor local adverse events were reported after vaccination. Seroconversion for the three antigens tested was higher after IM vaccination, although not statistically significant. Local antibody response to the three antigens tested was detected in 50-53% and 19-26% of IN and IM immunized subjects, respectively. The IN vaccine tested was significantly more effective than the IM vaccine in inducing mucosal IgA response. This may prevent influenza at its early stages and thus contribute to the reduction of complications in the elderly. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745240

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.

Authors:  D Chen; S B Periwal; K Larrivee; C Zuleger; C A Erickson; R L Endres; L G Payne
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.

Authors:  Heinz Arnold; Dirk Bumann; Melanie Felies; Britta Gewecke; Meike Sörensen; J Engelbert Gessner; Joachim Freihorst; Bernd Ulrich von Specht; Ulrich Baumann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.

Authors:  Zachary R Sia; Kevin Chiem; Wei-Chiao Huang; Amal Seffouh; Amir Teimouri Dereshgi; Tara Hogan; Joaquin Ortega; Bruce A Davidson; Luis Martinez-Sobrido; Jonathan F Lovell
Journal:  J Virol       Date:  2022-09-15       Impact factor: 6.549

Review 4.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.

Authors:  Svetomir N Markovic; Vera J Suman; Wendy K Nevala; Louis Geeraerts; Edward T Creagan; Lori A Erickson; Kendrith M Rowland; Roscoe F Morton; William L Horvath; Mark R Pittelkow
Journal:  Am J Clin Oncol       Date:  2008-12       Impact factor: 2.339

6.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Authors:  Antoine Minne; Jamila Louahed; Sybille Mehauden; Benoît Baras; Jean-Christophe Renauld; Rita Vanbever
Journal:  Immunology       Date:  2007-05-22       Impact factor: 7.397

7.  Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Authors:  Iain Stephenson; Maria C Zambon; Anna Rudin; Anthony Colegate; Audino Podda; Roberto Bugarini; Giusseppe Del Giudice; Ada Minutello; Susan Bonnington; Jan Holmgren; Kingston H G Mills; Karl G Nicholson
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens.

Authors:  Nelson F Eng; Srinivas Garlapati; Volker Gerdts; Lorne A Babiuk; George K Mutwiri
Journal:  J Immune Based Ther Vaccines       Date:  2010-08-24

9.  Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Authors:  Hideki Hasegawa; Takeshi Ichinohe; Akira Ainai; Shin-Ichi Tamura; Takeshi Kurata
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

10.  Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.

Authors:  Akira Ainai; Shin-Ichi Tamura; Tadaki Suzuki; Elly van Riet; Ryo Ito; Takato Odagiri; Masato Tashiro; Takeshi Kurata; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2013-06-27       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.